Our Disease-Modifying #genetherapy reduces amyloid pathology, neuroinflammation, cell dead and rescues synaptic plasticity and memory. Don’t miss posters 142&147! We will be there today to discuss about new advances and future perspectives.#AAIC23#ENDALZ@ISTAART#Alzheimers
We are really pleased to announce that TETRANEURON has received positive feedback from the FDA during the pre-IND meeting, supporting our approach for our #genetherapy TET-101 for Alzheimer's Disease.
We are incredibly proud of our team!
Interesting article by @RitaRubin highlighting the need to look beyond #amyloid to a more holistic approach for developing #Alzheimers therapies guided by the #BiologyofAging. @TheADDF is laser-focused on cultivating a diverse pipeline https://t.co/tSYmSMS2E5 @JAMA_current
To deal with Alzheimer's disease, multifactorial therapies must be investigated. We need to take into account all the altered processes in the brain of patients who develop the disease.
Thanks' to @elEconomistaes for sharing our message
https://t.co/ReaJimjWpJ
Today we are participating in a Human Brain Project workshop. Thank you very much to the Polytechnical University of Madrid for inviting us!
https://t.co/1HV8eFc5wk
Tomorrow morning you will have the opportunity to discuss with @csanchezpuelles (247) and @Morgan7lan (248) about the multifactorial gene therapy for #Alzheimers disease effect on cognition, synaptic plasticity, cell death and neuroinflamation. #FENS2022#biotech#clinicaltrial
¿Cómo prevenir y abordar el desgaste físico, psíquico, emocional y el riesgo de aislamiento social de los cuidadores al cargo de personas con #demencia ?
Manual de la Confederación Española de Alzhéimer @AlzheimerCeafa
https://t.co/0VrLHHtJJR
🗣Nuestro CEO, Jesús Rodrigo, continúa en la #ADI2022 de @AlzDisInt que se celebra hasta el día 11 en #Londres para ver el Plan de acción mundial de la @WHO.
Hoy modera la Plenaria 3 “Mes Mundial del #Alzheimer y Comunidades Amigas de la #Demencia: prioridades urgentes”
Estamos orgullosos de anunciar la incorporación de Álvaro Pascual Leone a nuestro Scientific Advisory Board. El Dr. Pascual-Leone ha sido reconocido como uno de los 15 neurocientíficos más relevantes del mundo. ¡Bienvenido Álvaro!
https://t.co/MHXPXM4D0G
TETRANEURON will be in London at the 8th LSX World Congress #LSXleaders
If you are interested in investing in an innovative gene therapy for Alzheimer's Disease, reach out to schedule a 1:1 meeting with M.Carmen Alvarez Abril & David Mor
https://t.co/Ltig2bYOK2